These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33587122)

  • 1. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents.
    McMillan M; Wang B; Koehler AP; Sullivan TR; Marshall HS
    Clin Infect Dis; 2021 Jul; 73(1):e233-e237. PubMed ID: 33587122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia.
    Marshall HS; McMillan M; Koehler AP; Lawrence A; Sullivan TR; MacLennan JM; Maiden MCJ; Ladhani SN; Ramsay ME; Trotter C; Borrow R; Finn A; Kahler CM; Whelan J; Vadivelu K; Richmond P
    N Engl J Med; 2020 Jan; 382(4):318-327. PubMed ID: 31971677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of
    Marshall HS; McMillan M; Koehler A; Lawrence A; MacLennan JM; Maiden MCJ; Ramsay M; Ladhani SN; Trotter C; Borrow R; Finn A; Sullivan T; Richmond P; Kahler CM; Whelan J; Vadivelu K
    BMJ Open; 2018 Jul; 8(7):e020988. PubMed ID: 29991629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of
    Marshall HS; McMillan M; Koehler A; Lawrence A; MacLennan J; Maiden M; Ramsay M; Ladhani SN; Trotter C; Borrow R; Finn A; Sullivan T; Richmond P; Kahler C; Whelan J; Vadivelu K
    BMJ Open; 2019 May; 9(5):e027233. PubMed ID: 31064808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
    Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R
    Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B Part of It School Leaver Study: A Repeat Cross-Sectional Study to Assess the Impact of Increasing Coverage With Meningococcal B (4CMenB) Vaccine on Carriage of Neisseria meningitidis.
    McMillan M; Koehler AP; Lawrence A; Sullivan TR; Bednarz J; MacLennan JM; Maiden MCJ; Ladhani SN; Ramsay ME; Trotter C; Borrow R; Finn A; Kahler CM; Whelan J; Vadivelu K; Richmond PC; Marshall HS
    J Infect Dis; 2022 Feb; 225(4):637-649. PubMed ID: 34487174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).
    Efron A; Biolchi A; Sorhouet Pereira C; Tomei S; Campos J; De Belder D; Moscoloni MA; Santos M; Vidal G; Nocita F; Vizzotti C; Pizza M
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288389. PubMed ID: 38111094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
    Castilla J; García Cenoz M; Abad R; Sánchez-Cambronero L; Lorusso N; Izquierdo C; Cañellas Llabrés S; Roig J; Malvar A; González Carril F; Boone ALD; Pérez Martín J; Rodríguez Recio MJ; Galmés A; Caballero A; García Rojas A; Juanas F; Nieto M; Viloria Raymundo LJ; Martínez Ochoa E; Rivas AI; Castrillejo D; Moreno Pérez D; Martínez A; Borràs E; Sánchez Gómez A; Pastor E; Nartallo V; Arteagoitia JM; Álvarez-Fernández B; García Pina R; Fernández Arribas S; Vanrell J; García Hernández S; Mendoza RM; Méndez M; López-Tercero MM; Fernández-Rodríguez Á; Blanco Á; Carrillo de Albornoz FJ; Ruiz Olivares J; Ruiz-Montero R; Limia A; Navarro-Alonso JA; Vázquez JA; Barricarte A
    N Engl J Med; 2023 Feb; 388(5):427-438. PubMed ID: 36724329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.
    Argante L; Abbing-Karahagopian V; Vadivelu K; Rappuoli R; Medini D
    BMC Infect Dis; 2021 Dec; 21(1):1244. PubMed ID: 34895161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy.
    Lodi L; Barbati F; Amicizia D; Baldo V; Barbui AM; Bondi A; Costantino C; Da Dalt L; Ferrara L; Fortunato F; Guarnieri V; Icardi G; Indolfi G; Martinelli D; Martini M; Moriondo M; Nieddu F; Peroni DG; Prato R; Ricci S; Russo F; Tirelli F; Vitale F; Ladhani SN; Azzari C;
    JAMA Netw Open; 2023 Aug; 6(8):e2329678. PubMed ID: 37594762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022.
    Rodrigues CMC; MacDonald L; Ure R; Smith A; Cameron JC; Maiden MCJ
    mBio; 2023 Apr; 14(2):e0049923. PubMed ID: 37036356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Meningococcal B (4CMenB) Vaccine on Pharyngeal Neisseria meningitidis Carriage Density and Persistence in Adolescents.
    McMillan M; Walters L; Sullivan T; Leong LEX; Turra M; Lawrence A; Koehler AP; Finn A; Andrews RM; Marshall HS
    Clin Infect Dis; 2021 Jul; 73(1):e99-e106. PubMed ID: 32447370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.